2021 Research News
Kevin Kilgore, PhD, staff scientist in the departments of Orthopaedics and Physical Medicine and Rehabilitation (PM&R), was awarded a $2.6M, 4-year grant from National Institutes of Health. The goal of the project is to develop an implanted device that can measure health status and predict disease states.
The proposed implanted device, called the "Lifeline", measures parameters such as body temperature, photoplethysmogram, electrocardiogram, audio, and acceleration. Taken together, these measures may be able to predict the early onset of autonomic dysreflexia (specific to spinal cord injury (SCI)), pneumonia, urinary tract infections, and pulmonary embolism. These comorbidities are among the top causes of death in SCI. Early treatment may prevent them from progressing to life-threatening conditions. The Lifeline device will be incorporated into an existing modular implant system that Dr. Kilgore's team has previously developed, called the "Networked Neuroprosthesis."
Dr. Kilgore is the P. Hunter Peckham and George J. Picha Professor of Biomedical Engineering in the Dept. of Orthopaedics and PM&R, Case Western Reserve University (CWRU). His co-investigators include Niloy Bhadra, MD, PhD, Associate Professor, Dept. PM&R, CWRU; Michael Fu, PhD, Assistant Professor, Dept. Electrical, Computer & Systems Engineering and PM&R, CWRU; Pedram Mohseni, PhD, Professor of Electrical, Computer, & Systems Engineering, CWRU; Laleh Najafizadeh, PhD, Associate Professor of Electrical & Computer Engineering, Rutgers University; and Brian Smith, BScHons, Director of Implant Development, Biomedical Engineering, CWRU.
MetroHealth has formed a new cancer research team to improve outcomes for all patients. The team, which is backed by millions of dollars in support and grants and dozens of research assistants, will also focus on ending the racial, ethnic, social, and economic inequities that impact cancer diagnosis and treatment.
The MetroHealth Center for Cancer Research team includes:
- Bingcheng Wang, PhD, Director of the Division of Cancer Biology in the Department of Medicine and Director of Basic Sciences in the MetroHealth Research Institute, has assembled an impressive team of cancer researchers who are bringing cutting-edge care to The MetroHealth System and its hundreds of thousands of patients.
- William Tse, MD, is training blood cells to become cancer-killing CAR T cells so patients can beat cancer without the toxic side effects of chemotherapy and radiation.
- Khalid Sossey-Alaoui, PhD, is working to understand why triple-negative breast cancer occurs much more often in African-American women so he can help end the dreaded disease.
- Zhisan Wang, MD, PhD, is searching for the biological signal in patients’ bodies that tell doctors lung cancer is there – long before it becomes deadly.
“We’re doing this for the patients we serve, to ensure that they have the latest advances in cancer care and that they are able to participate in cutting-edge clinical trials in cancer care," says Bernard Boulanger, MD, MetroHealth Executive Vice President and Chief Clinical Officer. Clinical trials give patients access to newly discovered medical testing and treatments before they’re available to the public.Learn More
Shari Bolen, MD, Director of the MetroHealth Population Health Research Institute (PHRI), and Aleece Caron, PhD, Co-Director of Education for the MetroHealth PHRI were awarded a 4-year, $4.1 million grant from The Agency for Healthcare Research and Quality (AHRQ) entitled "Achieving Outstanding Cardiovascular Health for All Ohioans: a Statewide Cardiovascular Health Collaborative (Cardio-OH).
The goal of the grant is to improve cardiovascular health and reduce cardiovascular health disparities for all Ohioans. They will work with primary care teams, patients and families, and statewide partners to develop a heart-healthy intervention program that primary care clinics in Ohio can use to improve care and reduce disparities for patients with high blood pressure, high cholesterol and who smoke.
Drs. Bolen and Caron are Associate Professors of Medicine at the Case Western Reserve University School of Medicine.
Dr. Ashwini (Ash) Sehgal will be the inaugural Director of Research and Evaluation for the Institute for H.O.P.E.™ in the Population Health Innovation Institute (PHII) at The MetroHealth System.
The mission of the Institute for H.O.P.E.™ is to identify and help eliminate barriers to optimal individual and community health and well-being through improving social influencers of health and addressing the root causes of health disparities in the Northeast Ohio region. In this new role, Dr. Sehgal will foster the missions of the PHII and the Population Health Research Institute (PHRI) to generate new knowledge, inform and target health and health care improvement initiatives, and conduct program evaluation to improve the health and health equity of the communities we serve.
He will continue to serve as co-director with Dr. Daryl Thornton for the Center for Reducing Health Disparities within PHRI while supporting enhanced collaboration between PHRI and PHII.
Bingcheng Wang, PhD, Director of the Division of Cancer Biology within the Department of Medicine, was appointed MetroHealth Research Institute Director of Basic Sciences, effective January 4, 2021. As Director, Dr. Wang will further develop basic and translational sciences research at The MetroHealth System (MHS) and guide its continued growth in alignment with System mission and vision.
Dr. Wang received his PhD in Toxicology and Oncology from the University of Wisconsin-Madison where his innovative research on breast cancer led to the award of one of the first three US biotechnology patents. Dr. Wang joined La Jolla Cancer Research Foundation for postdoctoral training where he honed his skills in small peptide-based cancer therapeutics. He joined MetroHealth and Case Western Reserve University (CWRU) School of Medicine in 1997.
Dr. Wang is an internationally-renowned cancer biologist who has many publications in top journals including Cancer Cell, Nature Cell Biology and Science Signaling. His laboratory focuses on how a group of essential cell surface communication molecules called receptor tyrosine kinases controls malignant behavior of cancer cells. His team has made multiple contributions to the field. His laboratory has been continuously funded by the National Institute of Health (NIH), DoD and a number of private foundations. He served as a program leader in the National Cancer Institute-designated Case Comprehensive Cancer for 10 years, first leading the Genitourinary Program and then the Molecular Oncology Program. Nationally he is a regular reviewer for many of the top journals and served for over 20 years on study sections of NIH, DoD, ACS and other agencies and foundations.
Dr. Wang has been the inaugural Director of the Division of Cancer Biology in the Department of Medicine since 2014. Under the new strategic vision of research at MetroHealth, Dr. Wang had a major role in the successful recruitment of four new basic and translational cancer researchers, all of whom are nationally recognized and talented investigators with prestigious grants from NIH.
Dr. Wang is currently Professor in the Department of Medicine at CWRU and holds the John A. and Josephine B. Wootton Endowed Chair in Research. He also holds appointments in Departments of Pharmacology and Physiology and Biophysics and is a member of the Case Comprehensive Cancer Center.
The MetroHealth System’s Population Health Research Institute’s Center for Clinical Informatics Research and Education is part of one of eight multi-center NIH R61 grants awarded to investigate COVID-19 in the pediatric population.
David Kaelber, MD, is site PI for MetroHealth on the grant entitled “COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to Predict Sick Children)”.
The primary goal of the grant is to develop robust predictive models in pediatric patients to predict who is likely and not likely to develop severe COVID-19 illness (short-term and long-term).
Because COVID-19 appears relatively rare in children and severe short-term and long-term COVID-19 related illnesses are even rarer in children, large databases will be needed to develop these robust predictive models.
MetroHealth’s primary role will be in providing access to and consultative expertise in using large electronic health record derived data sets including: Cosmos, IBM Watson Health Explorys, and TriNetX.
Each of these large data sets now contains data on over 70 million patients, of which 10-20 million are pediatric patients.
In January 2021, the PHRI Center for Health Care Research and Policy and Case Western Reserve University (CWRU) School of Medicine faculty were awarded a three-year $4.1 million grant from The Agency for Healthcare Research and Quality led by Drs. Shari Bolen and Aleece Caron to expand a statewide Ohio cardiovascular health collaborative (Cardi-OH).
This grant brings together leaders at The MetroHealth System, University Hospitals, Case Western Reserve University, Ohio State University, University of Cincinnati, and three regional health improvement collaboratives (The Health Collaborative, The Healthcare Collaborative of Greater Columbus, and Better Health Partnership) across the state along with many other state professional organizations, payers, community organizations, and other partners to improve cardiovascular health and reduce cardiovascular health disparities for all Ohioans.
To do this, they will work with primary care teams, patients and families to develop a heart healthy intervention that primary care clinics in Ohio can use to improve care and reduce disparities for patients with high blood pressure, high cholesterol and who smoke.
In November 2020, PHRI faculty member Dr. Aleece Caron was awarded a $450,000 grant from Project ECHO via the Agency for Healthcare Research and Quality (AHRQ) ECHO National Nursing Home COVID-19 Action Network.
This grant will provide training to 118 congregant living facilities in Ohio on critical and timely topics to decrease the risk of nursing home prevalence and spread of COVID-19. To do this, we assembled a team of clinicians and local experts in nursing home administration, infectious disease, geriatrics, and quality improvement to provide a 16-week training program.
We are currently offering four 90-minute sessions each week led by MetroHealth faculty including Drs. James Campbell, Eileen Seeholzer, Ann Avery, Patricia Campbell, Lorella Luezas Shamakian, and Tiffany Leake, APRN. In addition, this grant creates a rapid response framework to provide urgent, immediate technical assistance, resources, and guidance to nursing homes that experience outbreaks and other emergencies.